The Status of Vaccine Development Against the Human Cytomegalovirus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32134478.
- Also identified by DOI 10.1093/infdis/jiz447 and PMC identifier 7057802.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in development. Whereas the previous article [1] provides background and opinions about the issues relating to vaccination, this article provides specifics about the vaccines in active development, as reported at a National Institutes of Health-sponsored meeting in Bethesda on September 4-6, 2018. Here, vaccine developers provide synopses of their candidate vaccines to immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hematopoietic stem calls. The projects are presented here roughly in the descending order of their stage of development in the opinion of the first author.
Medical subject headings
- Cytomegalovirus
- Cytomegalovirus Infections
- Cytomegalovirus Vaccines